FC
DGX icon

Fairpointe Capital’s Quest Diagnostics DGX Stock Holding History

Fairpointe Capital’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		$705K Sell
5,494
-78,708
-93% -$9.7M 1.06% 33
2020
Q4 		$10M Sell
84,202
-24,250
-22% -$2.96M 1.84% 29
2020
Q3 		$12.4M Sell
108,452
-1,766
-2% -$209K 1.99% 29
2020
Q2 		$12.6M Sell
110,218
-22,884
-17% -$2.43M 1.83% 33
2020
Q1 		$10.7M Sell
133,102
-189,017
-59% -$19.6M 1.6% 33
2019
Q4 		$34.4M Sell
322,119
-322,784
-50% -$33.7M 2.64% 15
2019
Q3 		$69M Sell
644,903
-89,250
-12% -$9.16M 3.51% 5
2019
Q2 		$74.7M Sell
734,153
-206,649
-22% -$19.9M 3.05% 8
2019
Q1 		$84.6M Buy
940,802
+45,366
+5% +$3.93M 2.82% 11
2018
Q4 		$74.6M Buy
895,436
+116,790
+15% +$10.9M 2.56% 13
2018
Q3 		$84M Sell
778,646
-47,969
-6% -$5.26M 2.16% 25
2018
Q2 		$90.9M Sell
826,615
-72,281
-8% -$7.53M 2.12% 25
2018
Q1 		$90.2M Sell
898,896
-1,683
-0.2% -$172K 1.88% 30
2017
Q4 		$88.7M Buy
900,579
+17,775
+2% +$1.69M 1.67% 34
2017
Q3 		$82.7M Buy
882,804
+30,321
+4% +$3.22M 1.63% 33
2017
Q2 		$94.8M Sell
852,483
-81,919
-9% -$8.66M 1.89% 26
2017
Q1 		$91.7M Sell
934,402
-48,885
-5% -$4.66M 1.79% 27
2016
Q4 		$90.4M Sell
983,287
-54,526
-5% -$4.7M 1.83% 28
2016
Q3 		$87.8M Sell
1,037,813
-69,179
-6% -$5.81M 1.98% 26
2016
Q2 		$90.1M Sell
1,106,992
-497,253
-31% -$37.9M 2.04% 26
2016
Q1 		$115M Sell
1,604,245
-131,935
-8% -$8.85M 2.38% 21
2015
Q4 		$124M Sell
1,736,180
-180,784
-9% -$12.2M 2.23% 23
2015
Q3 		$118M Sell
1,916,964
-226,533
-11% -$15.8M 2.01% 28
2015
Q2 		$155M Sell
2,143,497
-173,369
-7% -$12.8M 2.17% 22
2015
Q1 		$178M Sell
2,316,866
-438,297
-16% -$31.4M 2.35% 16
2014
Q4 		$185M Sell
2,755,163
-66,396
-2% -$4.19M 2.43% 19
2014
Q3 		$171M Sell
2,821,559
-23,963
-0.8% -$1.48M 2.29% 17
2014
Q2 		$167M Buy
2,845,522
+259,700
+10% +$15.2M 2.23% 21
2014
Q1 		$150M Buy
+2,585,822
New +$139M 2.04% 25

Other funds holding DGX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FMI
Fiduciary Management Inc Milwaukee, Wisconsin $8.06B AUM 6.78% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DSA
Davis Selected Advisers Tucson, Arizona $21.8B AUM 23.45% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $107B AUM 24.58% 1-Year Est. Return

Fairpointe Capital's DGX Position: Q1 2021 in Review

Fairpointe Capital reduced its Quest Diagnostics (DGX) stake by 93% in Q1 2021, selling an estimated $9.7M and leaving 5,494 shares worth $705K. The position accounts for 1.06% of the portfolio, ranked #33.

Fairpointe Capital first reported a position in DGX in Q1 2014 and has held it in 29 quarters since. The position peaked at $185M in Q4 2014. 818 funds tracked by Wall St. Rank hold DGX as of Q1 2021.

  • Fairpointe Capital held 5,494 shares of Quest Diagnostics worth $705K as of Q1 2021.
  • Fairpointe Capital sold 78,708 Quest Diagnostics shares in Q1 2021, an estimated $9.7M.
  • Quest Diagnostics made up 1.06% of Fairpointe Capital's portfolio in Q1 2021, its #33 holding.
  • Fairpointe Capital first reported a position in Quest Diagnostics in Q1 2014 and has held it in 29 quarters since.
  • Fairpointe Capital's Quest Diagnostics position peaked at $185M in Q4 2014.
  • 818 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2021.

Based on Fairpointe Capital's 13F filing for Q1 2021, filed 13 May 2021.